why choose us

First received: May 21, 2023

Clinical Trial: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Breast Cancer

Study Type: INTERVENTIONAL


Official Title: A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer: ARIADNE

Brief Summary: The goal of this clinical trial is to compare trastuzumab deruxtecan (T-DXd) to standard preoperative treatment in patients with non-metastatic HER2-positive breast cancer.The main questions it aims to answer are:is T-DXd more effective than standard preoperative treatment?are there markers in the tumor or blood of patients with HER2-positive breast cancer that can help us predict response to treatment?Participants will be divided into two groups, where one group will be treated with three courses of T-DXd and the…

Read more